Ropeginterferon alfa-2b not checked

PharmaEssentia · P1101

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
8 active
16 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
Interferon alfa-2b FDA class
How it’s given
“Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg”In the company’s words, NCT04285086 on ClinicalTrials.gov
Tested for
Essential Thrombocythemia (2 trials), Polycythemia Vera (2 trials), Polycythemia Vera (PV), Primary Myelofibrosis, Myeloproliferative Neoplasm
Main trialPhase 3
“This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.”In the company’s words, NCT04285086 on ClinicalTrials.gov
Other names
P1101 · BESREMI
Copy of
Pegintron (Schering)Tested side by side with the original in NCT04382937
Given with
Pegasys (Pharmaand Gmbh)Other companies’ drugs in its trials

Other drugs for Essential Thrombocythemia

All 16 drugs for Essential Thrombocythemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 12 Nov 2024 Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Phase 3Active, not recruiting 30 Jun 2025 A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Phase 3Recruiting 30 Jun 2026 Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Phase 3Active, not recruiting 18 Nov 2027 P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Phase 2Active, not recruiting 7 Sep 2022 A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Phase 2Active, not recruiting 9 May 2025 A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Phase 4Withdrawn 31 Dec 2026 Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Phase 3Completed 15 Jul 2020 Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
Phase 3Completed 26 Jul 2024 A Study to Evaluate P1101 in Japanese PV Patients
Phase 2Completed 22 Nov 2016 Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Phase 2Completed 8 Mar 2021 Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
Phase 1Completed 26 Jun 2010 Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects
Phase 1Completed 18 Jul 2022 The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Phase 1Completed 8 Apr 2026 The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Phase 3Authorised not given A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments
Phase 2Authorised not given A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL (BosuPeg)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ropeginterferon alfa-2b

Following is part of Solo: you see every change to Ropeginterferon alfa-2b the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in